Results from the LIBRETTO-001 trial in patients pre-treated with standard therapies showed an objective response rate (ORR) of 61.5% for RET fusion-positive NSCLC, 77.6% for RET-mutated MTC, and 85.4% for RET fusion-positive TC [9,10]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.